HER-2 amplification
HER-2 amplification
|
Breast Cancer
Breast Cancer
|
neratinib
Knight Therapeutics Press Release - 3 weeks
|
HER-2 amplification
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
|
HER-2 amplification
HER-2 amplification
|
Breast Cancer
Breast Cancer
|
Zercepac (trastuzumab biosimilar)
|
HER-2 amplification
HER-2 amplification
|
|
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
|
HER-2 amplification
HER-2 amplification
|
|
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
|
HER-2 amplification
HER-2 amplification
|
|
trastuzumab + lapatinib
Sensitive: A2 - Guideline
|
HER-2 amplification
HER-2 amplification
|
Rectal Cancer
Rectal Cancer
|
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
|
HER-2 amplification
HER-2 amplification
|
Rectal Cancer
Rectal Cancer
|
trastuzumab + lapatinib
Sensitive: A2 - Guideline
|
HER-2 amplification
HER-2 amplification
|
Rectal Cancer
Rectal Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
trastuzumab
Sensitive: B - Late Trials
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab
Sensitive: B - Late Trials
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab
Sensitive: B - Late Trials
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
lapatinib
Sensitive: B - Late Trials
|
HER-2 amplification
HER-2 amplification
|
Breast Cancer
Breast Cancer
|
lapatinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Breast Cancer
Breast Cancer
|
tucatinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab + trastuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Breast Cancer
Breast Cancer
|
trastuzumab + tucatinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
afatinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Urothelial Cancer
Urothelial Cancer
|
afatinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
|
pyrotinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Esophageal Cancer
Esophageal Cancer
|
ibrutinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Breast Cancer
Breast Cancer
|
eFT226
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Breast Cancer
Breast Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
avelumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Esophageal Cancer
Esophageal Cancer
|
avelumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
HM 78136B
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Endometrial Cancer
Endometrial Cancer
|
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
|
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
rivoceranib + pyrotinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
|
panitumumab
Resistant: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Gallbladder Cancer
Gallbladder Cancer
|
trastuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Gallbladder Cancer
Gallbladder Cancer
|
lapatinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Gallbladder Cancer
Gallbladder Cancer
|
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Cholangiocarcinoma
Cholangiocarcinoma
|
trastuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
|
KN046 + KN026
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Bladder Cancer
Bladder Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Biliary Tract Cancer
Biliary Tract Cancer
|
pyrotinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Urothelial Cancer
Urothelial Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
cabazitaxel
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
gefitinib
Resistant: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Endometrial Cancer
Endometrial Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Endometrial Cancer
Endometrial Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Endometrial Cancer
Endometrial Cancer
|
pyrotinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
erlotinib
Resistant: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Ovarian Cancer
Ovarian Cancer
|
pyrotinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Prostate Cancer
Prostate Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Ovarian Cancer
Ovarian Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
neratinib + ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Pancreatic Cancer
Pancreatic Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
pyrotinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
dacomitinib
Resistant: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
|
cetuximab
Resistant: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Ovarian Cancer
Ovarian Cancer
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Uterine Cancer
Uterine Cancer
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Biliary Tract Cancer
Biliary Tract Cancer
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Cholangiocarcinoma
Cholangiocarcinoma
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
HER2 inhibitor
Resistant: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Uterine Cancer
Uterine Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
|
pembrolizumab
Sensitive: C4 – Case Studies
|
HER-2 amplification
HER-2 amplification
|
Cholangiocarcinoma
Cholangiocarcinoma
|
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: C4 – Case Studies
|
HER-2 amplification
HER-2 amplification
|
|
afatinib
Sensitive: C4 – Case Studies
|
HER-2 amplification
HER-2 amplification
|
|
afatinib
Sensitive: C4 – Case Studies
|
HER-2 amplification
HER-2 amplification
|
Cutaneous Melanoma
Cutaneous Melanoma
|
ado-trastuzumab emtansine
Sensitive: C4 – Case Studies
|
HER-2 amplification
HER-2 amplification
|
Cholangiocarcinoma
Cholangiocarcinoma
|
trastuzumab + pertuzumab
Sensitive: C4 – Case Studies
|
